CEBPA and acute myeloid leukemia: Katzerke demonstrated that the transcription factor-CCAAT enhancer binding protein alpha (C/EBPalpha) up-regulates the expression level of miR-30c in acute myeloid leukemia (AML) withNOTCH1as the direct target of miR-30c, indicating that miR-30c may be a novel biomarker and therapeutic targets of AML62.